Prenatal diagnosis of Duchenne muscular dystrophy: failure of amniotic fluid and maternal serum N tau-methylhistidine analyses to detect affected fetuses.
N tau-Methylhistidine (MH) and creatinine levels were determined in amniotic fluid and maternal serum from 81 women undergoing midtrimester amniocentesis for reasons other than the diagnosis of neuromuscular disease. Samples were also examined in three pregnancies with male fetuses who were subsequently found to have Duchenne muscular dystrophy (DMD). Between 16 and 20 weeks' gestation, amniotic fluid and maternal serum MH levels averaged 3.22 and 1.94 mumoles/L, respectively. No significant differences were found between the control and affected fetuses for MH and creatinine levels or for MH/creatinine ratios from amniotic fluid or maternal serum. Determination of amniotic fluid MH level thus has no apparent value in the prenatal diagnosis of DMD.
D000653:Amniotic Fluid / Q000032:analysis*; D003404:Creatinine / Q000032:analysis / Q000097:blood; D005069:Evaluation Studies as Topic; D005260:Female; D006639:Histidine / Q000031:analogs & derivatives*; D006801:Humans; D008762:Methylhistidines / Q000032:analysis* / Q000097:blood; D009136:Muscular Dystrophies / Q000175:diagnosis* / Q000378:metabolism; D011247:Pregnancy; D011296:Prenatal Diagnosis / Q000379:methods*
D008762:Methylhistidines; D006639:Histidine; D003404:Creatinine; C028118:3-methylhistidine